Overview

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Status:
Terminated

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).

Phase:

Phase 2

Details

Lead Sponsor:

Furiex Pharmaceuticals, Inc

Treatments:

Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination